Breeze Holdings Acquisition Corp. stockholders approve the business combination with YD Biopharma Limited.
The combined company will operate as YD Bio Limited and trade on Nasdaq under the ticker symbol "YDES".
The closing of the transaction is expected within the next two weeks.
Approved Business Combination
Stockholders voted in favor of the Business Combination with 3,127,474 shares in favor and only 1,000 shares against.
New Ticker Symbol
The combined company will trade on Nasdaq under the new ticker symbol "YDES".
Closing Expectation
The closing is expected to occur within the next two weeks, subject to customary closing conditions.
- YD Biopharma focuses on developing innovative vaccines and therapeutic biologics for infectious diseases and other indications.
- The transaction approval signifies a significant step towards the merger between Breeze Holdings Acquisition Corp. and YD Biopharma Limited.
The approval by Breeze Holdings Acquisition Corp. shareholders marks a crucial milestone in the business combination with YD Biopharma Limited, setting the stage for the future operations of the combined company as YD Bio Limited.